Trastuzumab Deruxtecan in Patients With HER2-Mutant Metastatic Non–Small-Cell Lung Cancer: Primary Results From the Randomized, Phase II DESTINY-Lung02 Trial The ASTRRA trial highlights both the power ...
SAN ANTONIO – Patients with early-stage, node-negative, hormone receptor (HR)-positive, HER2- negative breast cancer who have a high risk of recurrence based on the OncotypeDX genomic test had better ...
Credit: Getty Images. Adding everolimus to adjuvant endocrine therapy does not improve survival for patients with HR+, HER2- breast cancer. Adding 1 year of everolimus to standard adjuvant endocrine ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results